Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2024

Oya Yuko, Imaizumi Kazuyoshi, Mitsudomi Tetsuya

Abstract excerpt

The Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the first driver oncogenes identified in human cancer in the early 1980s. However, it has been deemed 'undruggable' for nearly four decades until the discovery of KRAS G12C covalent inhibitors, which marked a pivotal breakthrough. Currently, sotorasib and adagrasib have been approved by the US FDA to treat patients with non-small cell lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Identifiers

PMID: 39047616
DOI: 10.1016/j.lungcan.2024.107886

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?PMID 39047616Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.Semantic proximity Read ↗

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Semantic proximity Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read ↗

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.Semantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

Differential Response and Resistance to KRAS-Targeted Therapy.Semantic proximity Read ↗

Small molecular inhibitors for KRAS-mutant cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.